Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease
PMID: 38644588
Source: Aliment Pharmacol Ther
Publication date:
2025-07-24
Year:
2024
Abstract
NULL